Plasmatech Biopharmaceuticals Inc. (PTBI) 6.61 $PT
Post# of 273242
Posted On: 09/17/2016 11:08:53 AM
Plasmatech Biopharmaceuticals Inc. (PTBI) 6.61 $PTBI
Abeona Therapeutics (Nasdaq: ABEO), formerly known as PlasmaTech Biopharmaceuticals, Inc. to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri Jun 19, 9:00AM CDT
What:
PTBI: 6.61 (+0.08), NDAQ: 69.47 (-0.05), ABEO: 4.86 (-0.11)
PlasmaTech Biopharmaceuticals Announces Name Change to Abeona Therapeutics to Reflect Broader Rare Disease Commitment
Marketwired - Fri Jun 19, 7:03AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced a name change to Abeona Therapeutics, Inc. to reflect its broader rare disease commitment. The Company expects that its common stock will begin trading on NASDAQ on Monday, June 22, under the ticker symbol ABEO, along with announcing Abeona Therapeutics to ring the Nasdaq Stock market closing bell on Monday, June 22nd at 4:00 pm ET. Live streaming can be found at: https://new.livestream.com/nasdaq/live)
PTBI: 6.61 (+0.08)
PlasmaTech Biopharmaceuticals to Present at the 2015 BIO International Convention
Marketwired - Wed Jun 17, 6:03AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announced today that Tim Miller, Ph.D., President & CEO, will be presenting at the 2015 BIO International Convention at the Pennsylvania Convention Center. Management is available throughout the conference for the one-on-one meetings as well.
PTBI: 6.61 (+0.08)
PlasmaTech Biopharmaceuticals Expands Rare Disease Pipeline With License Agreement for Gene Therapy in Fanconi Anemia & CRISPR/Cas9-Based Technology Platform for Rare Blood Disorders
Marketwired - Mon Jun 15, 6:03AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI)
PTBI: 6.61 (+0.08)
PlasmaTech Biopharmaceuticals Announces License Agreement for AAV Gene Therapy to Treat Patients With Juvenile Batten Disease
Marketwired - Mon Jun 08, 6:03AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI)
PTBI: 6.61 (+0.08)
Male Infertility - Pipeline Review, H1 2015
M2 - Fri Jun 05, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/877pz8/male_infertility) has announced the addition of the "Male Infertility - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Male Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Infertility and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaMab Co., Ltd - Pantarhei Bioscience BV - PharmaEssentia Corporation - PlasmaTech Biopharmaceuticals, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (oxytocin estrogen) - Biosimilar 4 for Acute Myocardial Infarction and Infertility - Biosimilar 5 for Infertility - Biosimilar 6 for Infertility - Biosimilar 7 for Infertility and Oncology - LM-001 - LM-002 - MCS-5 - Oral Fertility Drugs - PEG-FSH - Small Molecule to Agonize FSHR for Infertility - Small Molecules for Male Infertility - Stem Cell Therapy for Male Infertility For more information visit http://www.researchandmarkets.com/research/87...nfertility
PTBI: 6.61 (+0.08)
PlasmaTech Biopharmaceuticals to Present at the 2015 Jefferies Healthcare Conference
Marketwired - Mon Jun 01, 9:37AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announced today that they will be presenting at the 2015 Jefferies Conference at the Grand Hyatt Hotel. Management is available throughout the conference for the one-on-one meetings as well.
PTBI: 6.61 (+0.08)
PlasmaTech Biopharmaceuticals to Present at the 2015 LD Micro Invitational Conference
Marketwired - Fri May 29, 12:29PM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announced today that they will be presenting at the 2015 LD Micro Invitational Conference. Management is available throughout the conference for the one-on-one meetings as well.
PTBI: 6.61 (+0.08)
Abeona Therapeutics (Nasdaq: ABEO), formerly known as PlasmaTech Biopharmaceuticals, Inc. to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri Jun 19, 9:00AM CDT
What:
PTBI: 6.61 (+0.08), NDAQ: 69.47 (-0.05), ABEO: 4.86 (-0.11)
PlasmaTech Biopharmaceuticals Announces Name Change to Abeona Therapeutics to Reflect Broader Rare Disease Commitment
Marketwired - Fri Jun 19, 7:03AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced a name change to Abeona Therapeutics, Inc. to reflect its broader rare disease commitment. The Company expects that its common stock will begin trading on NASDAQ on Monday, June 22, under the ticker symbol ABEO, along with announcing Abeona Therapeutics to ring the Nasdaq Stock market closing bell on Monday, June 22nd at 4:00 pm ET. Live streaming can be found at: https://new.livestream.com/nasdaq/live)
PTBI: 6.61 (+0.08)
PlasmaTech Biopharmaceuticals to Present at the 2015 BIO International Convention
Marketwired - Wed Jun 17, 6:03AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announced today that Tim Miller, Ph.D., President & CEO, will be presenting at the 2015 BIO International Convention at the Pennsylvania Convention Center. Management is available throughout the conference for the one-on-one meetings as well.
PTBI: 6.61 (+0.08)
PlasmaTech Biopharmaceuticals Expands Rare Disease Pipeline With License Agreement for Gene Therapy in Fanconi Anemia & CRISPR/Cas9-Based Technology Platform for Rare Blood Disorders
Marketwired - Mon Jun 15, 6:03AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI)
PTBI: 6.61 (+0.08)
PlasmaTech Biopharmaceuticals Announces License Agreement for AAV Gene Therapy to Treat Patients With Juvenile Batten Disease
Marketwired - Mon Jun 08, 6:03AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI)
PTBI: 6.61 (+0.08)
Male Infertility - Pipeline Review, H1 2015
M2 - Fri Jun 05, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/877pz8/male_infertility) has announced the addition of the "Male Infertility - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Male Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Infertility and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaMab Co., Ltd - Pantarhei Bioscience BV - PharmaEssentia Corporation - PlasmaTech Biopharmaceuticals, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (oxytocin estrogen) - Biosimilar 4 for Acute Myocardial Infarction and Infertility - Biosimilar 5 for Infertility - Biosimilar 6 for Infertility - Biosimilar 7 for Infertility and Oncology - LM-001 - LM-002 - MCS-5 - Oral Fertility Drugs - PEG-FSH - Small Molecule to Agonize FSHR for Infertility - Small Molecules for Male Infertility - Stem Cell Therapy for Male Infertility For more information visit http://www.researchandmarkets.com/research/87...nfertility
PTBI: 6.61 (+0.08)
PlasmaTech Biopharmaceuticals to Present at the 2015 Jefferies Healthcare Conference
Marketwired - Mon Jun 01, 9:37AM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announced today that they will be presenting at the 2015 Jefferies Conference at the Grand Hyatt Hotel. Management is available throughout the conference for the one-on-one meetings as well.
PTBI: 6.61 (+0.08)
PlasmaTech Biopharmaceuticals to Present at the 2015 LD Micro Invitational Conference
Marketwired - Fri May 29, 12:29PM CDT
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announced today that they will be presenting at the 2015 LD Micro Invitational Conference. Management is available throughout the conference for the one-on-one meetings as well.
PTBI: 6.61 (+0.08)
(0)
(0)Scroll down for more posts ▼